lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

4 rows where filing_uuid = "3b3d64e7-7e64-40cc-afcd-e78794345f22" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: received_date (date)

issue_code 4

filing_year 1

filing_period 1

id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1445164 KNIGHT CAPITOL CONSULTANTS 3b3d64e7-7e64-40cc-afcd-e78794345f22 Q3 KNIGHT CAPITOL CONSULTANTS 40036301 GENZYME CORPORATION 2013 third_quarter TAX Possible changes in the tax code that affect the pharmaceutical industry, including the R&D tax credit and the Orphan Drug tax credit. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-10-16T19:33:34.300000-04:00
1445165 KNIGHT CAPITOL CONSULTANTS 3b3d64e7-7e64-40cc-afcd-e78794345f22 Q3 KNIGHT CAPITOL CONSULTANTS 40036301 GENZYME CORPORATION 2013 third_quarter HCR Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board. General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-10-16T19:33:34.300000-04:00
1445166 KNIGHT CAPITOL CONSULTANTS 3b3d64e7-7e64-40cc-afcd-e78794345f22 Q3 KNIGHT CAPITOL CONSULTANTS 40036301 GENZYME CORPORATION 2013 third_quarter MMM Budget and deficit reduction proposals that may affect the Medicare and Medicaid programs, including issues related to End Stage Renal Disease, and Sustainable Growth Rate and Average Sales Price calculations. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-10-16T19:33:34.300000-04:00
1445167 KNIGHT CAPITOL CONSULTANTS 3b3d64e7-7e64-40cc-afcd-e78794345f22 Q3 KNIGHT CAPITOL CONSULTANTS 40036301 GENZYME CORPORATION 2013 third_quarter PHA Adequate funding for programs of the Food and Drug Administration, including implementation of the Prescription Drug User Fee Act (FY 2014 appropriations for the FDA, H.R. 2410/S. 1244/H.J. Res. 59). Assess potential impact of sequestration on public health/food and drug programs (FY 2014 appropriations for HHS, S. 1284). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-10-16T19:33:34.300000-04:00

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);